Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141 (2021).

Article  CAS  PubMed  Google Scholar 

Zhang, J. J., Dong, X., Liu, G. H. & Gao, Y. D. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clin. Rev. Allergy Immunol. 64, 90 (2023).

Article  CAS  PubMed  Google Scholar 

Falahi, S. & Kenarkoohi, A. Host factors and vaccine efficacy: Implications for COVID‐19 vaccines. J. Med Virol. 94, 1330 (2022).

Article  CAS  PubMed  Google Scholar 

Zimmermann, P. & Curtis, N. Factors That Influence the Immune Response to Vaccination. Clin. Microbiol. Rev. 32, e00084-18 (2019).

Popkin, B. M. et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes. Rev. 21, e13128 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faizo, A. A. et al. A potential association between obesity and reduced effectiveness of COVID‐19 vaccine‐induced neutralizing humoral immunity. J. Med. Virol. 95, e28130 (2023).

Kara, Z. et al. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity. Obes. Surg. 32, 2987–2993 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Ou, X. et al. Antibody responses to COVID‐19 vaccination in people with obesity: A systematic review and meta‐analysis. Influenza Other Respir. Viruses 17, e13078 (2023).

van der Klaauw, A. A. et al. Accelerated waning of the humoral response to COVID-19 vaccines in obesity. Nat. Med 29, 1146 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Levin, E. G. et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N. Engl. J. Med. 385, e84 (2021).

Lobstein, T., Jackson-Leach, R., Powis, J., Brinsden, H. & Gray, M. World Obesity Atlas 2023. (World Obesity Federation, 2023).

Controlling the global obesity epidemic. https://www.who.int/activities/controlling-the-global-obesity-epidemic (2024).

Pugliese, G. et al. Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. Int J. Obes. (Lond.) 46, 449–465 (2022).

Article  CAS  PubMed  Google Scholar 

Obesity, Race/Ethnicity, and COVID-19, Overweight Obesity, CDC. https://www.cdc.gov/obesity/data/obesity-and-covid-19.html (2022).

Nasr, M. J. C., Geerling, E. & Pinto, A. K. Impact of Obesity on Vaccination to SARS-CoV-2. Front. Endocrinol. 13, 898810 (2022).

Szczerbiński, Ł. et al. Immune Response to Vaccination against COVID-19 at Different Second-Dose Intervals and Their Associations with Metabolic Parameters. Vaccines 11, 149 (2023).

Kara, Z. et al. Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity. Res. Artic. Obes. Facts 15, 648–654 (2022).

Article  CAS  Google Scholar 

Nam, S. Y., Jeon, S. W., Jung, D. K. & Heo, S. J. Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults. Infect. Chemother. 54, 504 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pellini, R. et al. Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI. Vaccines 9, 685 (2021).

Golec, M. et al. Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study. PLoS One 18, e0287128 (2023).

Phumisantiphong, U. et al. Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand. Vaccine X 13, 100277 (2023).

Wu, Y., Zhang, H., Meng, L., Li, F. & Yu, C. Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates. Front. Immunol. 13, 906457 (2022).

Naranbhai, V. et al. Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines. J. Infect. Dis. 225, 1141 (2022).

Article  CAS  PubMed  Google Scholar 

Ben Ahmed, M. et al. Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa). Vaccines 10, 1189 (2022).

Self, W. H. et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021. Morbidity Mortal. Wkly. Rep. 70, 1337 (2021).

Article  CAS  Google Scholar 

Tong, M. Z. W. et al. Elevated BMI reduces the humoral response to SARS‐CoV‐2 infection. Clin. Transl Immunol. 12, e1476 (2023).

Balkan, İ. İ. et al. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required. Ir. J. Med Sci. 192, 19 (2023).

Article  CAS  PubMed  Google Scholar 

Kotsiou, O. S. et al. The Comparative Superiority of SARS-CoV-2 Antibody Response in Different Immunization Scenarios. J. Pers. Med. 12, 1756 (2022).

Hidayat, R. et al. Evaluation of SARS-CoV-2 Antibody Response Post Third Dose COVID-19 mRNA Vaccination at Universitas Indonesia Hospital. Acta Med. Acad. 51, 69 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Bayart, J. L. et al. Confounding factors influencing the kinetics and magnitude of serological response following administration of nt162b2. Microorganisms 9, 1340 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pellini, R. et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine 36, 100928 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Held, J. et al. Reactogenicity correlates only weakly with humoral immunogenicity after COVID-19 vaccination with BNT162b2 mRNA (Comirnaty®). Vaccines 9, 1063 (2021).

Ali, H. et al. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination. Front. Immunol. 12, 752233 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bates, J. T. et al. IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity. Vaccines 10, 512 (2022).

Wu, J., Mu, H., Pan, X. & Guo, W. Studying the effects of booster shots and antibody responses to the SARS-CoV-2 vaccination over time in health personnel. Front. Cell Infect. Microbiol. 13, 1138631 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh, A. K. et al. Humoral antibody kinetics with ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study. Diabetes Metab. Syndr. 16, 102424 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cherry, N. et al. Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study. Vaccine 42, 1168–1178 (2024).

Article  CAS  PubMed  Google Scholar 

Campo, F. et al. Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers. Vaccines 9, 1125 (2021).

Barocci, S. et al. Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination. Vaccines 10, 491 (2022).

Coggins, S. A. et al. Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers. Open Forum Infect. Dis. 9, ofab575 (2022).

Papaioannidou, P. et al. Age, Sex and BMI Relations with Anti-SARS-CoV-2-Spike IgG Antibodies after BNT162b2 COVID-19 Vaccine in Health Care Workers in Northern Greece. Microorganisms 11, 1279 (2023).

Lee, S. W. et al. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions. Front. Immunol. 12, 779212 (2021).

Kara, Z. et al. Antibody Response to Inactive SARS-CoV-2 Vaccination in a Cohort of Elderly Patients Living with Obesity. Obes. Facts 16, 374 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palacka, P. et al. Effectiveness, Adverse Events, and Immune Response Following Double Vaccination with BNT162b2 in Staff at the National Comprehensive Cancer Center (NCCC). Vaccines 10, 558 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe, M. et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine.https://doi.org/10.1002/dmrr.3465 (2021).

Keeshan, A. et al. Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination. BMJ Open 13, 77714 (2023).

Article  Google Scholar 

Kim, J. S. et al. Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study. Nat Commun 15, 1492 (2024).

Yamamoto, S. et al. Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine. Obesity 30, 999 (2022).

Article  CAS  PubMed  Google Scholar 

Garner-Spitzer, E. et al. Obesity and Sex Affect the Immune Responses to Tick-Borne Encephalitis Booster Vaccination. Front Immunol. 11, 860 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

AbdelWareth, L. et al. Natural infection versus hybrid (natural and vaccination) humoral immune response to SARS-CoV-2: a comparative paired analysis. Front Immunol. 14, 1230974 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Dolscheid-Pommerich, R. et al. Correlation between a quantitative anti‐SARS‐CoV‐2 IgG ELISA and neutralization activity. J. Med Virol. 94, 388 (2022).

Article  CAS  PubMed  Google Scholar